Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.
about
Disability Rating Scales in Parkinson's Disease: Critique and Recommendations.Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.Baseline Plasma C-Reactive Protein Concentrations and Motor Prognosis in Parkinson DiseaseQuantitative Susceptibility Mapping in Parkinson's Disease.Outcome measures for Parkinson's disease dementia: a systematic review.CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.Quantitative susceptibility mapping of the midbrain in Parkinson's diseaseCreatine Revealed Anticonvulsant Properties on Chemically and Electrically Induced Seizures in Mice.Levodopa alone compared with levodopa-sparing therapy as initial treatment for Parkinson's disease: a meta-analysis.Beyond muscles: The untapped potential of creatine.The Key Determinants to Quality of Life in Parkinson's Disease Patients: Results from the Parkinson's Disease Biomarker Program (PDBP).Dynamics of change in self-reported disability among persons with Parkinson's disease after 2 years of follow-up.Predictors of Functional Decline in Early Parkinson's Disease: NET-PD LS1 Cohort.Dance for PD: a preliminary investigation of effects on motor function and quality of life among persons with Parkinson's disease (PD).Earlier Intervention with Deep Brain Stimulation for Parkinson's Disease.Autonomic and electrocardiographic findings in Parkinson's disease.Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
P2860
Q30250276-E988B8EF-D114-4733-BD8D-2A3C5EAA2BF1Q30357397-7C25066D-DC1A-4DF5-860F-2455097DA748Q35755849-5353AA5A-CE57-4517-8607-75C900A56BE1Q36123740-D9C16EF0-2EBB-4884-A678-2BCCC7BB2D2AQ36688859-6791DF90-271B-4847-982B-C08EC0200A76Q37272860-C7EEB648-BD19-4367-A680-47A416B8F372Q37650486-06BAF98F-1F0A-4537-982F-287CE55B1850Q37651130-40708C39-014B-459C-8B26-28D34E54402DQ38485023-7A370AB6-DBE2-4CF7-9AC6-A51C1B743064Q38700215-B5E3CA4B-A5F7-4320-B448-E4223975FD8BQ38852910-1874E511-7492-4FE1-9ECD-C6C8FA2035BFQ40202303-5D261EBD-4403-49F1-B743-C4BD7CA83B73Q40240247-FC3F2EAF-1D7B-4FAB-8B71-BCA6326B25AAQ41120927-15D33A95-07BF-4BBF-858A-612DE5433101Q41690001-DE445931-BE02-4106-B94D-DE3C2CF305B9Q45228075-47E506C2-C1EE-4C2C-A2C6-2AC9B5F388F1Q45945368-4BDFCB09-BE85-4416-9706-A5A13E0C7816
P2860
Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Measuring disease progression ...... n Disease (NET-PD) experience.
@ast
Measuring disease progression ...... n Disease (NET-PD) experience.
@en
Measuring disease progression ...... ry Trials in Parkinson Disease
@nl
type
label
Measuring disease progression ...... n Disease (NET-PD) experience.
@ast
Measuring disease progression ...... n Disease (NET-PD) experience.
@en
Measuring disease progression ...... ry Trials in Parkinson Disease
@nl
prefLabel
Measuring disease progression ...... n Disease (NET-PD) experience.
@ast
Measuring disease progression ...... n Disease (NET-PD) experience.
@en
Measuring disease progression ...... ry Trials in Parkinson Disease
@nl
P2093
P2860
P1433
P1476
Measuring disease progression ...... n Disease (NET-PD) experience.
@en
P2093
Barbara C Tilley
G Webster Ross
Grace S Liang
Ivan Bodis-Wollner
Kevin M Biglan
Lisa M Shulman
NET-PD Investigators
Sotirios A Parashos
P2860
P304
P356
10.1001/JAMANEUROL.2014.391
P407
P577
2014-06-01T00:00:00Z